Anaptysbio Inc (ANAB) Stock Price, Quote & News

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared co...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 362 6295

Website: www.anaptysbio.com

Address:

10770 Wateridge Circle, Suite 210, San Diego, United States

JarvisFlow Dec. 11 at 1:17 PM

Stifel has updated their rating for AnaptysBio ( $ANAB ) to Buy with a price target of 56.

0 · Reply

StockBraker Dec. 10 at 10:34 PM

$ANAB

0 · Reply

StockBraker Dec. 3 at 9:50 PM

$ANAB https://www.investing.com/news/company-news/anaptysbio-stock-hits-52week-high-at-4335-usd-93CH-4389213

0 · Reply

Reanimated666 Dec. 3 at 8:54 PM

$ANAB Higher Highs

0 · Reply

Reanimated666 Dec. 2 at 3:26 PM

$ANAB Long!

0 · Reply

Reanimated666 Dec. 1 at 9:15 PM

$ANAB number 1 IBD 50

0 · Reply

StockBraker Dec. 1 at 1:25 PM

$ANAB Volume PM is negligible (11 shares) at the moment

0 · Reply

StockBraker Nov. 27 at 1:48 PM

$ANAB Share price is up 70% since my post on 9/29. Most recent 5 analysts' PTs of the 11 covering are shown below. New consensus is $66. Expect further updates to come in next month. Off to prep the turkey - Happy Thanksgiving everyone 🦃🥧🌽

0 · Reply

TheOrangeBall Nov. 25 at 11:24 PM

$ANAB Why is this 40 dollars a share? Their book value is negative, their cash flow is negative, and their liabilities are more than their assets??? I don't understand the stock market.

2 · Reply

RunnerSignals Nov. 25 at 8:27 PM

$ANAB $AVAV $BLSH $CALX $IMTX Pipeline magic and tech muscle! Immunology, drones, fiber, and cancer therapies. trading floor excitement on max https://stocksrunner.com/news/2025-11-25-stock-upgrades-today-see-wall-street-boost-confidence

0 · Reply

Anaptys Announces Participation in December Investor Conferences

Nov 21, 2025, 8:52 AM EST - 20 days ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

GSK

Nov 21, 2025, 8:48 AM EST - 20 days ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK

Nov 21, 2025, 6:14 AM EST - 20 days ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

GSK

Nov 21, 2025, 4:00 AM EST - 20 days ago

Anaptys Announces $100 Million Stock Repurchase Plan

Nov 21, 2025, 3:50 AM EST - 20 days ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GSK

Nov 13, 2025, 7:30 AM EST - 4 weeks ago

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Nov 10, 2025, 12:30 PM EST - 4 weeks ago

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

Nov 10, 2025, 9:00 AM EST - 4 weeks ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Nov 4, 2025, 4:15 PM EST - 5 weeks ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:15 PM EST - 5 weeks ago

Anaptys Announces Participation in November Investor Conferences

Oct 29, 2025, 9:15 AM EDT - 6 weeks ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Oct 15, 2025, 5:37 AM EDT - 2 months ago

AnaptysBio, Inc. - Special Call

Oct 13, 2025, 9:15 AM EDT - 2 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Sep 30, 2025, 1:59 PM EDT - 2 months ago

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Sep 29, 2025, 4:05 PM EDT - 2 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 2 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Aug 27, 2025, 4:15 PM EDT - 3 months ago

Anaptys Announces Participation in September Investor Conferences

Aug 6, 2025, 8:56 PM EDT - 4 months ago

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

Aug 6, 2025, 4:15 PM EDT - 4 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 10, 2025, 1:33 PM EDT - 6 months ago

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Jun 6, 2025, 3:39 PM EDT - 6 months ago

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

Jun 4, 2025, 2:23 PM EDT - 6 months ago

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Jun 3, 2025, 4:05 PM EDT - 6 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

May 27, 2025, 4:15 PM EDT - 7 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 5, 2025, 4:15 PM EDT - 7 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Mar 24, 2025, 9:15 AM EDT - 9 months ago

Anaptys Announces Stock Repurchase Plan

Feb 27, 2025, 4:15 PM EST - 10 months ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 10 months ago

Anaptys Announces Participation in March Investor Conferences

Feb 12, 2025, 7:30 AM EST - 10 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 11, 2025, 5:30 PM EST - 10 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 3, 2025, 4:15 PM EST - 11 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 7:30 AM EST - 11 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Jan 7, 2025, 9:15 AM EST - 1 year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 2:07 PM EST - 1 year ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 10:20 AM EST - 1 year ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 1 year ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:30 AM EST - 1 year ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Aug 23, 2024, 7:26 AM EDT - 1 year ago

Why AnaptysBio Was Such a Healthy Stock This Week

Aug 15, 2024, 2:14 PM EDT - 1 year ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 14, 2024, 5:00 AM EDT - 1 year ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 5, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 2:53 PM EDT - 1 year ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

May 9, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 1 year ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:05 PM EDT - 1 year ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

PGEN XOMA

Apr 12, 2024, 7:00 PM EDT - 1 year ago

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

JarvisFlow Dec. 11 at 1:17 PM

Stifel has updated their rating for AnaptysBio ( $ANAB ) to Buy with a price target of 56.

0 · Reply

StockBraker Dec. 10 at 10:34 PM

$ANAB

0 · Reply

StockBraker Dec. 3 at 9:50 PM

$ANAB https://www.investing.com/news/company-news/anaptysbio-stock-hits-52week-high-at-4335-usd-93CH-4389213

0 · Reply

Reanimated666 Dec. 3 at 8:54 PM

$ANAB Higher Highs

0 · Reply

Reanimated666 Dec. 2 at 3:26 PM

$ANAB Long!

0 · Reply

Reanimated666 Dec. 1 at 9:15 PM

$ANAB number 1 IBD 50

0 · Reply

StockBraker Dec. 1 at 1:25 PM

$ANAB Volume PM is negligible (11 shares) at the moment

0 · Reply

StockBraker Nov. 27 at 1:48 PM

0 · Reply

TheOrangeBall Nov. 25 at 11:24 PM

$ANAB Why is this 40 dollars a share? Their book value is negative, their cash flow is negative, and their liabilities are more than their assets??? I don't understand the stock market.

2 · Reply

RunnerSignals Nov. 25 at 8:27 PM

0 · Reply

StockBraker Nov. 25 at 1:37 PM

$ANAB https://www.tipranks.com/news/ratings/buy-rating-for-anaptysbio-amid-legal-dispute-with-tesaro-over-jemperli-rights-ratings

0 · Reply

StockBraker Nov. 25 at 1:35 PM

$ANAB ICYMI https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-100-million-stock-repurchase-plan

0 · Reply

SaraStewart Nov. 24 at 4:26 PM

$ANAB

0 · Reply

RunnerSignals Nov. 24 at 3:53 PM

$ANAB Clean high with improving momentum. Could continue higher

0 · Reply

StockBraker Nov. 24 at 3:12 PM

$ANAB Awesomeness 🥰

0 · Reply

JarvisFlow Nov. 24 at 2:57 PM

Wedbush has adjusted their stance on AnaptysBio ( $ANAB ), setting the rating to Outperform with a target price of 50.

0 · Reply

JarvisFlow Nov. 24 at 2:56 PM

HC Wainwright & Co. has adjusted their stance on AnaptysBio ( $ANAB ), setting the rating to Buy with a target price of 52 → 51.

0 · Reply

Reanimated666 Nov. 24 at 1:37 PM

$ANAB The earnings here have been impressive and has been pumped by many investment clubs. Wouldn’t be surprised to see this keep gapping

0 · Reply

WallStreetBuyDip Nov. 22 at 5:19 AM

$ANAB Massive volume spike of 1,525,400 shares, way above the average of 714,973. Price hit a high of $39.65 from a low of $12.38. Recent price action saw significant jumps. Smart move to wait for a lower H% before considering an entry.

0 · Reply

RunnerSignals Nov. 21 at 10:34 PM

$NVRI just sold Clean Earth for $3B while $GCT and $ANAB are still figuring out their board game https://stocksrunner.com/news/2025-11-21-bull-of-the-day-nvri-stock-surges-on-strategic-clean-earth-sale-deal

0 · Reply

StockBraker Nov. 21 at 10:27 PM

$ANAB Or that?

0 · Reply

StockBraker Nov. 21 at 10:25 PM

$ANAB How can you be unhappy with that?

0 · Reply

Market Cap	1.21B
Revenue (ttm)	91.28M
Net Income (ttm)	-145.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-159.10%
Debt to Equity Ratio	0.00

Volume	318,200
Avg Vol	537,046
Day's Range	N/A - N/A
Shares Out	27.69M
Stochastic %K	75%
Beta	0.29
Analysts	Strong Sell
Price Target	$63.91